Florida 2025 2025 Regular Session

Florida House Bill H1297 Analysis / Analysis

Filed 03/30/2025

                    STORAGE NAME: h1297b.HHS 
DATE: 3/30/2025 
 	1 
      
FLORIDA HOUSE OF REPRESENTATIVES 
BILL ANALYSIS 
This bill analysis was prepared by nonpartisan committee staff and does not constitute an official statement of legislative intent. 
BILL #: HB 1297 
TITLE: Electronic Prescribing 
SPONSOR(S): Partington 
COMPANION BILL: SB 1568 (Brodeur) 
LINKED BILLS: None 
RELATED BILLS: SB 1568 (Brodeur) 
Committee References 
 Health Professions & Programs 
18 Y, 0 N 

Health & Human Services 
 
 
SUMMARY 
 
Effect of the Bill: 
HB 1297 aligns Florida’s exceptions to the electronic prescribing requirement with federal exceptions for electronic 
prescribing by removing state-specific exemptions and adding federal exemptions.  
 
Fiscal or Economic Impact: 
The bill will have an indeterminate, negative fiscal impact on the state government. See Fiscal or Economic Impact. 
 
  
JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 
ANALYSIS 
EFFECT OF THE BILL: 
Electronic Prescribing  
 
Florida law requires prescribers who have an electronic health record system to prescribe all medications 
electronically unless one of eight exemptions apply. Current federal regulations require prescribers to 
electronically prescribe controlled substances under a Medicare Part D drug plan unless one of three exemptions 
apply.  
 
The bill aligns Florida’s exceptions to the electronic prescribing requirement with the federal exceptions for 
electronic prescribing by removing state-specific exemptions and adding federal exemptions. Specifically, the bill 
requires all prescribers, not just those who have an electronic health record system, to prescribe all medications 
electronically unless:  
 
 The Department of Health issues a waiver to the prescriber  because the prescriber cannot meet the 
requirement due to circumstances beyond the prescriber’s control; 
 The prescriber issues 100 or fewer prescriptions per year; or 
 The prescriber is in the geographic areas for which a state of emergency is declared pursuant to s. 252.36. 
(Section 1) 
 
Under current law, the Department of Health (DOH) receives and investigates complaints against prescribers who 
fail to comply with the electronic prescribing requirements on behalf of the regulatory boards.
1 Current law 
authorizes the regulatory boards, or DOH if there is no regulatory board, to determine any disciplinary action 
against the prescriber. DOH is responsible for ensuring that prescribers comply with the terms and penalties 
imposed by the regulatory boards.
2  
 
The bill updates cross references. (Sections 2 and 3) 
                                                            
1
 The Boards of Medicine, Osteopathic Medicine, Podiatric Medicine, Dentistry, Nursing, and Optometry.  
2
 Ss. 456.072 and 456.073, F.S.   JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	2 
 
The bill provides an effective date of July 1, 2025. (Section 4) 
 
FISCAL OR ECONOMIC IMPACT:  
 
STATE GOVERNMENT:  
The Department of Health (DOH) will incur nonrecurring costs for rulemaking, which can be absorbed within 
current resources. DOH will also incur nonrecurring increase in workload associated with notifying and 
communicating changes to electronic prescribing requirements, which can be absorbed within current resources.
3  
 
 
RELEVANT INFORMATION 
SUBJECT OVERVIEW: 
Electronic Prescribing 
 
Electronic prescribing (e-prescribing) is the use of an electronic device such as a computer or tablet to enter and 
securely transmit prescriptions to pharmacies using special software and connectivity to a transmission network, 
rather than writing a prescription on paper.
4 Numerous benefits have been attributed to e-prescribing including, 
improved prescription accuracy, increase patient safety, reduction of opportunities for fraud, and cost reduction.
5 
 
Patient Safety 
 
An adverse drug event (ADE) is harm experienced by the patient as a result of exposure to medicine.
6 Each year, 
ADEs account for approximately 700,000 emergency department visits and 100,000 hospitalizations.
7 Some ADEs 
occur unrelated to hospital care, such as overdoses of opioid medications.
8 Medication errors most commonly 
occur during the prescribing, ordering, and administration stage; approximately 50% of medication errors occur 
when a medication is prescribed or ordered.
9 It is estimated that about half of ADEs are preventable.
10 E-
prescribing can help reduce errors due to illegible handwriting, lost paper scripts, and incomplete or inaccurate 
instructions.
11  
 
Fraud 
 
Individuals may illegally obtain prescription medication by using fraudulent, forged, or altered written 
prescriptions. In an effort to reduce fraud related to the use or misuse of controlled substances, Florida law 
requires prescribers to use counterfeit-proof prescription pads purchased from an authorized supplier for written 
                                                            
3
 Department of Health, 2025 Agency Legislative Bill Analysis on HB 1297, on file with the Health Professions & Programs 
Subcommittee.  
4
 The Office of the National Coordinator for Health Information Technology, What is Electronic Prescribing?, 
https://www.healthit.gov/faq/what-electronic-prescribing (last visited Mar. 17, 2025).  
5
 Agency for Health Care Administration, Florida Electronic Prescribing Annual Report for 2023, 
https://ahca.myflorida.com/content/download/25388/file/2023eRxAnnualReport_Final.pdf (last visited Mar. 17, 2025).  
6
 U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality, Medication Errors and Adverse 
Drug Events (last rev. Sep. 2019), https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events (last visited 
Mar. 17, 2025).  
7
 Id. 
8
 Id.  
9
 Rayhan A. Tariq, Rishik Vashisht, Ankur Sinha, et al., Medication Dispensing Errors and Prevention, [Feb, 2024], available at 
https://www.ncbi.nlm.nih.gov/books/NBK519065/ (last visited Mar. 17, 2025).  
10
 Id. 
11
 Matthew E. Hirschtritt, M.D., M.P.H., Steven Chan, M.D., M.B.A, and Wilson O.Ly, Pharm.D,M.Sc, Realizing E-Prescribing’s 
Potential to Reduce Outpatient Psychiatric Medication Errors, [2017], available at 
https://psychiatryonline.org/doi/10.1176/appi.ps.201700269 (last visited Mar. 17, 2025).   JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	3 
prescriptions for controlled substances.
12 A counterfeit-proof prescription pad must include the following 
features:
13 
 
 A background color that is blue or green and resists reproduction; 
 Printed on artificial watermarked paper; 
 Resists erasures and alterations; and 
 The word “void” or “illegal” must appear on any photocopy or reproduction; 
 
Health care practitioners and health care facilities must return unused counterfeit-proof prescription to the vendor 
to be destroyed.
14 Even with these precautions, there is still the danger of a legitimate prescription pad being 
stolen from a health care practitioner’s office or a health care facility and fraudulent prescriptions written.
15 
 
E-prescribing eliminates the risk of stolen prescription pads and, with the two-factor authentication required by 
the U.S. Drug Enforcement Administration (DEA), may further reduce unauthorized or altered prescriptions.
16  
 
Efficiency 
 
E-prescribing creates efficiencies for prescribers, patients, and pharmacies. For prescribers, e-prescribing can be 
integrated into electronic health records, which includes patient information such as clinical notes, laboratory 
results, and clinical decision support functions.
17 E-prescribing also improves the accuracy of prescriptions and 
helps guide clinical decision-making by checking the appropriateness of a prescription and connecting to a 
patient’s health insurance for its formulary.
18 Prescribers have also indicated that less time is spent resolving 
issues with pharmacies, including prior authorizations and refill requests, allowing more time to be spent on 
patient care.
19 The software also automates certain tasks which allows staff to perform other functions. Such 
efficiencies may ultimately lower overall operating costs. 
 
Patients may also benefit from e-prescribing efficiencies due to the ability of the prescriber to check for drug 
interactions, drug allergies, and whether a particular drug is covered by their insurance. This may enable patients 
to reduce copayment expenses or inconvenience associated with requesting an alternate medication from the 
prescriber if the drug prescribed is not covered or too expensive.
20 
 
Finally, pharmacies will likely benefit from e-prescribing efficiencies because it reduces the time spent on 
interpreting a prescription. Pharmacists must contact prescribers if a prescription is illegible or inconsistent, 
which affords the pharmacist more time to counsel patients.
21 
 
As noted above, ADEs result in many emergency room visits and hospitalizations, as well as additional visits to the 
prescriber’s office. Although e-prescribing will not prevent all ADEs,
22 they may reduce the number of ADEs due to 
                                                            
12
 S. 456.42, F.S. 
13
 Rule 64B-3.005, F.A.C. 
14
 Id. 
15
 U.S. Department of Justice, Drug Enforcement Administration, Diversion Control Division, A Pharmacist’s Guide to 
Prescription Fraud, (Feb. 2000), available at https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-002R1)(EO-
DEA009R1)_RPH_Guide_to_RX_Fraud_Trifold_(Final).pdf  (last visited Mar. 17, 2025). 
16
 National Association of Chain Drug Stores, Opioid Abuse Epidemic: Solutions from the Front Lines of Care, (last rev. May 
2019), available at https://www.nacds.org/pdfs/government/2017/Opioid-Policy-Oct-2017.pdf (last visited Mar. 17, 2025). 
17
 Amber Porterfield, et. al., Electronic Prescribing: Improving the Efficiency and Accuracy of Prescribing in the Ambulatory Care 
Setting, Perspect. Health Inf. Manage. 2014 Spring: 11 (Apr. 2014), available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995494/ (last visited Mar. 17, 2025). 
18
 Academy of Managed Care Pharmacy, Concept Series Paper on Electronic Prescribing, available at 
https://amcp.org/sites/default/files/2019-03/Electronic%20Prescribing.pdf (last visited Mar. 17, 2025). 
19
 Supra, note 17. 
20
 Id. 
21
 Amina Hareem, Joshua Lee, et al., Benefits and Barriers Associated with E-prescribing in Community Pharmacy—A systemic 
Review, available at https://pmc.ncbi.nlm.nih.gov/articles/PMC10746557/ (last visited Mar. 17, 2025).   JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	4 
improved prescribing and the assistance of decision support systems.
23 The efficiencies noted above may also lead 
to a reduction to overall operating costs. 
 
Electronic Prescribing for Controlled Substances Application Requirements 
 
E-prescribing relies on specialized software to securely generate and transmit sensitive information between the 
health care provider and pharmacy. All applications used for electronically prescribing controlled substances 
(EPCS) must meet standards established by the DEA.
24 All prescriptions issued electronically for controlled 
substances must meet these requirements regardless of whether the patient is under Medicare Part D. EPCS 
software must be capable of authenticating prescriber and patient identities, detecting irregularities, and 
preventing duplication, among other technical security standards.
25 
 
The DEA implements the Comprehensive Drug Abuse Prevention and Control Act of 1970, often referred to as the 
Controlled Substances Act.
26 In 2010, the DEA adopted a rule authorizing prescriber to issue electronic 
prescriptions for controlled substances and permitted pharmacies to receive, dispense, and archive these 
electronic prescriptions.
27 To e-prescribe controlled substances, a prescriber must:
28  
 
 Purchase or use DEA-compliant software that supports e-prescribing; 
 Complete the identity-proofing process to acquire a two-factor authentication credential or digital 
certificate; 
 Attach the authentication credential to his or her identity; 
 Set access controls so that only individuals who may legally prescribe a controlled substance are allowed to 
do so; and 
 Access the e-prescribing or electronic health record platform. 
 
Cost of Implementation 
 
According to an industry analysis of e-prescribing software costs, the cost of a stand-alone e-prescribing system 
that meets the DEA’s requirements for EPCS ranges from $170 to $650, annually.
29 The fee for initial set-up of the 
software may be included; however, some vendors may charge additional fees for set-up and for a token for the 
two-factor authentication required by the DEA.
30 In 2018, a health IT management consulting company identified 
the estimated cost of adding on EPCS functionality to the most widely used EHR systems, as indicated by the table 
below.
31  
 
 
EHR 	EPCS Setup (One-time fee) Annual Ongoing Cost 
Allscripts Professional $340 per provider 	$150 per provider 
Allscripts Touchworks $6,000 per practice 	$150 per provider 
                                                                                                                                                                                                                             
22
 Some ADEs are unavoidable even if the medication is properly prescribed and administers. These are often known side 
effects of a medication. See supra note 6. 
23
 Supra, note 6. 
24
 The DEA establishes these requirements according to the agency’s responsibilities under the Controlled Substances Act. See, 
21 U.S.C. 829 (a) and 871(b). 
25
 21 CFR 1311.120 
26
 21 U.S.C. 801–971. 
27
 21 C.F.R. s. 1306.08 and 21 C.F.R. Part 1311. 
28
 Id. 
29
 Eclinicworks, E-prescribing of Controlled Substances, available at https://www.eclinicalworks.com/wp-
content/uploads/2016/11/ePrescribing-of-Controlled-Substances-Slick.pdf; RxNT, ERX, available at 
https://www.rxnt.com/eprescribing/ (last visited Mar. 17, 2025). See also, RxNT, ERX, 
https://www.rxnt.com/software/electronic-prescribing/ (last visited Mar. 30, 2025).  
30
 21 C.F.R. 1311. The U.S. Drug Enforcement Administration requires electronic prescribing software for controlled 
substances to have two-factor authentication to verify the identity of the prescriber and protect such credentials from misuse. 
31
Point of Care Partners, HIT Perspectives: The Impact of Cost on EPCS Adoption, (Apr. 2018), https://www.pocp.com/hit-
perspectives-cost-EPCS-Adoption (last visited Mar. 30, 2025).  JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	5 
Amazing Charts $0 	$250 per provider 
Aetna 	$0 	$0 per provider 
Cerner 	Varies based upon # of providers 
DrFirst 	$90 per provider 	$75 per provider 
eClinicalWorks $250 per provider 	$0 per provider 
E-MDs 	$225 per provider 	$120 per provider 
Epic 	Varies based upon # of providers 
GE Centricity  $0 	$5,988 per provider 
Greenway Intergy $150 per provider 	$90 per provider 
Greenway PrimeSuite $150 per provider 	$90 per provider 
NewCrop 	$150 per provider 	$150 per provider 
NextGen 	$0 	included in ePrescribing  
Practice Fusion $0 	included in ePrescribing 
 
Federal Requirements and Incentives 
 
The Health Information Technology for Economic and Clinical Health Act of 2009, authorized incentive payments 
through Medicare and Medicaid to health care practitioners and hospitals for meaningfully using EHRs to help 
offset some of the costs related to the adoption of electronic health record systems.
32 The incentive program 
consists of two stages. Stage one required the electronic capture of clinical data, including transmitting at least 40 
percent of eligible prescriptions electronically.
33 In stage two, health care providers must demonstrate meaningful 
use for a full year; stage two retains the objective that eligible prescriptions be transmitted electronically.
34 
Participants could choose to participate under Medicare or Medicaid, but could only participate in one of the 
programs. The maximum incentive available under Medicare was $44,000 across five years and under Medicaid, 
$63,750 across six years.
35 
 
Incentive payments for the Medicare program ended in 2016, and the Medicaid program ended in 2021.
36 The 
Centers for Medicare and Medicaid Services subsequently launched the Promoting Interoperability Program and 
implemented a merit-based incentive program to reward value and outcomes.
37 The focus of the program is on 
interoperability, improved flexibility, and placing emphasis on the use of electronic exchange of health information 
between patients and providers.
38 Promoting interoperability objectives, which includes the use of e-prescribing 
and EHRs, may account for up to 25 percent of the final score for the merit-based incentive.
39 
 
                                                            
32
 Medscape, EHR Incentive Programs: Achieving Meaningful Use, available at 
https://www.medscape.org/viewarticle/770841#content=0_0 (last visited Mar. 17, 2025). 
33
 Id. 
34
 Centers for Medicare and Medicaid Services, Stage 2 Overview Tipsheet, (Aug. 2012), available at 
https://www.cms.gov/regulations-and-guidance/legislation/ehrincentiveprograms/downloads/stage2overview_tipsheet.pdf 
(last visited Mar. 17, 2025). For the initial year of stage 2, CMS required providers to demonstrate meaningful use for 90 days, 
but in subsequent year the requirement is for a full year. 
35
 Centers for Medicare and Medicaid Services, An Introduction to the Medicare EHR Incentive Program for Eligible 
Professionals, available at https://www.cms.gov/Regulations-and-
Guidance/Legislation/EHRIncentivePrograms/Downloads/EHR_Medicare_Stg1_BegGuide.pdf (last visited Mar. 17, 2025). 
36
 Centers for Medicare and Medicaid Services, Medicare and Medicaid Promoting Interoperability Program Basics, (last rev. 
Aug. 2019), available at https://www.cms.gov/regulations-and-guidance/legislation/ehrincentiveprograms/basics.html (last 
visited Mar. 17, 2025). Participants must have enrolled to participate in the Medicaid program before 2016 to be eligible for 
incentive payments. 
37
 Id. 
38
 Id. 
39
 Centers for Medicare and Medicaid Services, Quality Payment Program, available at https://qpp.cms.gov/participation-
lookup/about?py=2019 (last visited Mar. 17, 2025), Centers for Medicare and Medicaid Services, Merit-based Incentive 
Payment System: Promoting Interoperability Requirements, available at https://qpp.cms.gov/mips/promoting-
interoperability?py=2019 (last visited Mar. 17, 2025), and Centers for Medicare and Medicaid Services, Quality Payment 
Program: Explore Measures, available at https://www.cms.gov/medicare/quality/measures (last visited Mar. 17, 2025).  JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	6 
According to the Office of the National Coordinator for Health Information Technology, approximately 80 percent 
of office-based physicians in Florida have adopted EHRs that meet the criteria for meaningful use.
40 The ONC also 
found that, as of June 2017, 97 percent of hospitals of Florida hospitals had adopted EHRs that meet the criteria for 
meaningful use.
41 
 
Federal Electronic Prescribing Requirements 
 
Federal policy does not broadly mandate the use of e-prescribing for prescriptions generally, nor controlled 
substances specifically. Federal policy establishes requirements for e-prescribing applications used in prescribing 
controlled substances in order to ensure secure and fraud-free transmissions. The only circumstance where the 
government mandates the use of e-prescribing is for controlled substances prescribed under a Medicare Part D 
drug plan. 
 
Medicare Part D Mandatory e-Prescribing 
 
Federal law requires all Schedule II-V controlled substances prescribed under a Medicare Part D drug plan to be 
prescribed electronically unless an exemption applies.
42 Currently, there are three exemptions: 
 
 The prescriber has obtained a CMS-approved waiver because the prescriber cannot meet the requirements 
due to circumstances beyond the prescriber’s control; 
 The prescriber issues 100 or fewer relevant prescriptions per year; or 
 The prescriber is in the geographic area of an emergency or disaster declared by a Federal, State, or local 
government entity. 
 
CMS monitors prescriber compliance through the EPCS Program. Prescribers who use e-prescribing for less than 
70 percent of annual prescribing for controlled substances under Medicare Part D are notified of their 
noncompliance which may be considered by CMS during the assessment for potential fraud, waste, and abuse.
43  
 
Florida Electronic Prescribing Requirements 
 
Current Florida law requires prescribers to prescribe electronically, but this requirement only applies to 
prescribers who have an electronic health record system. In addition, Florida law exempts prescribers from this 
requirement if: 
 
 The practitioner and the dispenser are the same entity; 
 The prescription cannot be transmitted electronically under the current national standard; 
 The practitioner has been issued a waiver by the Department of Health;
44 
 The practitioner determines that the use of e-prescribing would delay a patient’s access to a drug thus 
adversely impacting the patient’s medical condition; 
 The drug is being prescribed under a research protocol; 
 The prescription is for a drug which the federal Food and Drug Administration requires the prescription 
contain elements that may not be included in e-prescribing; 
 The prescription is for an individual receiving hospice care or a resident of a nursing home facility; or 
                                                            
40
 U.S. Department of Health and Human Services, Office of the National Coordinator for Health Information Technology, 
Florida Health IT Summary, available at https://dashboard.healthit.gov/apps/health-information-technology-data-
summaries.php?state=Florida&cat9=all+data (last visited Mar. 17, 2025). 
41
 Id. 
42
 P.L. 115-271, Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and 
Communities Act (SUPPORT Act). 
43
 Centers for Medicare & Medicaid (2024). CMS Electronic Prescribing for Controlled Substances (EPCS) Program. Available at 
https://www.cms.gov/medicare/e-health/eprescribing/cms-eprescribing-for-controlled-substances-program (last visited 
Mar. 17, 2025). 
44
 Waivers are not to exceed one year, and may be issued due to demonstrated economic hardship, technological limitations 
that are not reasonably within the control of the practitioner, or another exceptional circumstance demonstrated by the 
practitioner.  JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	7 
 The practitioner determines that it is in the best interest of the patient, or the patient determines that it is 
in his or her own best interest, to compare prescription drug prices among area pharmacies. The 
practitioner must document such determination in the patient’s medical record. 
 
Current law requires prescriptions that are electronically generated and transmitted to contain the following:
 45 
 
 The name of the prescriber; 
 The name and strength of the drug prescribed; 
 The quantity of the drug prescribed in numerical format;  
 Directions for use; 
Date and electronic signature of the prescriber. 
 
Under current law, e-prescribing software may not interfere with a patient’s choice of pharmacy or use any means, 
such as pop-up ads, advertising, or instant messaging, to influence or attempt to influence the prescribing decision 
of the prescriber at the point of care.
46 E-prescribing software may provide formulary information, as long as 
nothing makes it more difficult or precludes a prescriber from selecting a specific pharmacy or drug.
47 
 
E-Prescribing Requirements and Exemptions: Federal
48 vs State 
Exemptions 
Federal: 
Medicare Part D 
Patients 
Florida: 
All Patients 
Florida: 
HB 1297 
Controlled 
Substances 
All Drugs All Drugs 
1. Prescriber and dispenser are the same entity 	X  
2. Prescriber issues fewer than 100 relevant 
prescriptions annually 
X  	X 
3. Prescriber is located in a declared emergency 
or disaster area 
X  	X 
4. Prescriber issued a waiver due to 
circumstances outside the prescriber’s control 
X X X 
5. Prescriber does not maintain an electronic 
health record system 
 	X  
6. Prescription cannot be eRx under the most 
recent National Council for Prescription Drug 
Programs SCRIPT Standard 
 	X  
7. Prescriber determines it is impractical to 
obtain an eRx drug in a timely manner and 
such delay would adversely impact patient’s 
medical condition 
 	X  
8. Drug is being prescribed under a research 
protocol 
 	X  
9. FDA requires prescription elements not 
available in eRx 
 	X  
10. Patient is receiving hospice care or is a 
resident of a nursing home 
 	X  
                                                            
45
 S. 456.42, F.S. 
46
 S. 456.43, F.S. 
47
 Id. 
48
 The shaded cells were federal exemptions at the time the Florida e-prescribing exemptions became law but the federal 
government subsequently repealed them.  JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	8 
11. Prescriber or patient determines it is in the 
patient’s best interest to compare drug prices 
among pharmacies 
 	X  
 
 E-Prescribing Data 
 
The Agency for Health Care Administration (AHCA) maintains a clearinghouse of information on electronic 
prescribing, including trends on the adoption and use of e-prescribing in the state.
49 AHCA annually publishes a 
report on its website on the implementation of electronic prescribing by health care practitioners, facilities, and 
pharmacies.
50 The reports provide metrics on e-prescribing in Florida based on data provided by national e-
prescribing networks and Florida Medicaid.  
 
In its 2024 annual report, AHCA reported that the average number of e-prescriptions per month increased from 
372,085 in 2008 to 17,472,000 in 2023. The report also states that e-prescribers in the state increased by 106% 
with 73% of prescribers and 92% of pharmacies now capable of e-prescribing. The graph below indicates that 
growth.
51  
 
 
 
 
  
                                                            
49
 S. 408.0611, F.S. 
50
 Id., and Agency for Health Care Administration, Florida Center for Health Information and Transparency, Florida Electronic 
Prescribing Annual Report for 2023, (Nov. 2024), available at 
https://ahca.myflorida.com/content/download/25388/file/2023eRxAnnualReport_Final.pdf (last visited Mar. 17, 2024). 
51
 Agency for Health Care Administration, Florida Center for Health Information and Transparency, Florida Electronic 
Prescribing Annual Report for 2023, (Nov. 2024), available at 
https://ahca.myflorida.com/content/download/25388/file/2023eRxAnnualReport_Final.pdf (last visited Mar. 17, 2025).  JUMP TO SUMMARY 	ANALYSIS RELEVANT INFORMATION BILL HISTORY 
 	9 
 
BILL HISTORY 
COMMITTEE REFERENCE ACTION DATE 
STAFF 
DIRECTOR/ 
POLICY CHIEF 
ANALYSIS 
PREPARED BY 
Health Professions & Programs 
Subcommittee 
18 Y, 0 N 3/20/2025 McElroy Clenord 
Health & Human Services 
Committee 
  Calamas Clenord